John Schreiber, MD, FAES

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Zogenix
    Topic:
    fenfluramine for Dravet syndrome
    Date added:
    Date updated:
    07/27/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Neurocrine
    Topic:
    SCN8A
    Date added:
    Date updated:
    07/27/2023
Return to 2022 Epilepsy Board Review and Best Practices Course